Tandem Diabetes Care | TNDM - Interest Expense On Debt


Tandem Diabetes Care reported $874.65M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Abbott USD 42M 2M Dec/2025
Align Technology USD 2M 660K Mar/2023
AtriCure USD 1.35M 79K Jun/2025
Baxter International USD 58M 14M Sep/2025
Becton, Dickinson and Co. USD 155M 3M Sep/2025
Boston Scientific USD 87M 3M Sep/2025
Cooper Companies USD 24.4M 1000K Sep/2025
Dexcom USD 4.7M 0 Sep/2025
Edwards Lifesciences USD 38.6M 1.2M Sep/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Globus Medical USD 5.1B 5.1B Sep/2025
ICU Medical USD 42.04M 18.97M Sep/2025
Insulet USD 7M 2.5M Sep/2025
Integra LifeSciences USD 22.72M 1.68M Sep/2025
Intuitive Surgical USD 19.35B 811.4M Sep/2025
J&J USD 18M 290M Sep/2025
Masimo USD 8.8M 600K Sep/2025
Medtronic USD 181M 5M Sep/2025
Merit Medical Systems USD 6.78M 207K Jun/2025
Roche Holding CHF 304M 7.5M Jun/2025
Stryker USD 157M 46.17B Sep/2025
Tandem Diabetes Care USD 874.65M 872.75M Sep/2025
Teleflex USD 31.84M 10.13M Sep/2025
Zimmer Biomet Holdings USD 75.4M 3.9M Sep/2025